发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:Lack of head-to-head trials highlights a need for comparative real-world evidence of proteasome inhibitors plus Rd.Methods: In this retrospective, US population-representative EHR study of RRMM patients initiating IRd, KRd, or VRd in line of therapy (LOT) ≥2 between 1/2014 and 9/30/2018, 664 patients were treated in LOT ≥2 with: IRd, n = 168; KRd, n = 208; VRd, n = 357. Median age was 71/65/71 years; 67%/70%/75% had a frailtymodified score of intermediate/frail; 20%/28%/13% had high cytogenetic risk in I-/K-/V-Rd groups. Risk of PI-triplet discontinuation was lower for I- vs. K-Rd (HR: 0.71) and I- vs. V-Rd (HR: 0.85); unadjusted, median TTNTs (months): 12.7/8.6/14.2 (LOT ≥2) and 16.8/9.5/14.6 (LOT 2-3) (I-/K-/V-Rd). Adjusted TTNT was comparable between I-/K-/V-Rd in LOT ≥2 with a TTNT benefit among intermediate/frail patients for I- (HR: 0.70; P=0.04) and V- (HR: 0.73; P<0.05) vs. K-Rd. I/K/V-Rd triplets were comparable in TTNT overall, but IRd and VRd were associated with longer TTNT in intermediate/frail patients than KRd. The results suggest a trial-efficacy/real-world-effectiveness gap, especially for KRd, underlining the limited generalizability of trial results where >50% of patients are excluded. Individualized treatment based on patient characteristics, such as frailty status, is especially pertinent in an elderly RRMM population.
展开更多
最新影响因子:2.819 | 期刊ISSN:1747-4086 | CiteScore:1.81 |
出版周期: | 是否OA:YES | 出版年份:2008 |
自引率:3.60% | 研究方向:HEMATOLOGY- |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice. Areas covered include: • Acute leukemias • Anemias • Bleeding disorders • Bone marrow and hematopoietic stem cell transplantation • Cellular disorders • Chronic leukemias • Disorders of iron metabolism • Hodgkins disease • Infection in hematology • Immunodeficiency syndromes • Autoimmune diseases • Marrow failure syndromes • Multiple myeloma and amyloidosis • Neutropenia • Non-Hodgkin lymphomas • Pediatric hematology • Platelet disorders • Thrombosis and hemostasis • Transfusion medicine Expert Review of Hematology provides commentary and analysis to elucidate best clinical practice in hematology and to translate advances in research – in areas such as immunology, stem cell research, and cell and gene therapy – into the clinical context.
近年来,先进的分子研究技术已经改变了血液学。随着对血液病认识的提高,我们现在有机会研究和评估新的生物疗法、新药和药物组合、新的治疗计划和包括干细胞移植在内的新方法。我们还可以期待蛋白质组学、分子遗传学和生物标志物的研究能够促进新的诊断方法和合适的治疗方法的识别。随着我们对血细胞和造血组织的形成和功能的认识的进一步提高,对血液学家来说,采用这些新范式并制定综合策略来确定可能的最佳患者护理将是一个重大挑战。《血液学专家评论》(1747-4086)将这些进展纳入背景,并探讨如何将其直接转化为临床实践。 领域包括: •急性白血病 •贫血 •出血失调 •骨髓和造血干细胞移植 •细胞疾病 •慢性白血病 •铁代谢紊乱 •霍吉金斯疾病 •血液学感染 •免疫缺陷综合症 •自身免疫性疾病 •骨髓衰竭综合征 •多发性骨髓瘤和淀粉样变性 •嗜中性白血球减少症 •非霍奇金淋巴瘤 •儿科血液学 •血小板疾病 •血栓形成和止血 •输血医学 《血液学专家评论》提供评论和分析,阐明血液学的最佳临床实践,并将免疫学、干细胞研究、细胞和基因治疗等领域的研究进展转化为临床应用。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
HEMATOLOGY(血液学) 4区 |
48/71 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
104 | 0 | 104 |
引文计数(2018)
文献(2015-2017)
515次引用
285篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Hematology
|
#53/120
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
16年经验沉淀,实体公司
运营
影响因子:2.67
ISSN:1054-6006
研究方向:农林科学-海洋学
影响因子:3.906
ISSN:1054-3139
研究方向:农林科学-海洋学
影响因子:3.994
ISSN:0304-4203
研究方向:化学-海洋学
影响因子:5.763
ISSN:0022-2828
研究方向:医学-细胞生物学
影响因子:3.128
ISSN:2228-5806
研究方向:CELL BIOLOGY-
影响因子:5.063
ISSN:2044-5040
研究方向:CELL BIOLOGY-
影响因子:0.308
ISSN:0884-6812
研究方向:CELL BIOLOGY-
影响因子:2.5
ISSN:0025-3235
研究方向:地学-地球化学与地球物理
影响因子:2.049
ISSN:0377-0265
研究方向:地学-地球化学与地球物理
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务16年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表16年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
Expert Review of Hematology 投稿经验
(由下方点评分析获得,0人参与,3557人阅读)